Page 28 - Delaware Medical Journal - June 2017
P. 28
CANCER PROTOCOL
NCI PROTOCOL OF THE MONTH
URCC 13059 GAP: A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy for Advanced Cancer:
Reducing Chemotherapy Toxicity in Older Adults
Pimary Objective:
Our primary aim is to determine if providing information regarding geriatric assessment (GA) plus GA-driven recommendations to oncology physicians reduces clinician-rated grade 3-5 toxicity in participants aged 70 and over with advanced cancer starting a
new treatment regimen. The regimen must include a chemotherapy drug or other agents that have similar prevalence of toxicity. The new treatment regimen.
Secondary Objectives:
1. The principal secondary endpoint for this study is the proportion of participants that are alive at 6 months after study entry.
2.
We will compare treatment decisions. We will also compare the number and type of GA-driven recommendations
implemented for older participants starting a new treatment regimen for advanced cancer.
Exploratory Aims:
An exploratory aim is to determine whether providing the oncology team with GA information and GA-driven recommendations can slow functional and physical decline in older patients with advanced cancer.Functional status will be measured with self- reported Instrumental Activities of Daily Living score. Physical performance will be measured with the OARS Physical Health Subscale, and the Short Physical Performance Battery.
In collaboration with the National Cancer Institute, other exploratory aims will evaluate the role of patient-reported CTCAE in the clinical care of older adults receiving cancer treatment.
Eligibility:
Diagnosis of an advanced solid tumor malignancy (advanced cancer) or lymphoma. In most situations, this would be a stage IV cancer. Patients with a diagnosis of stage III cancer or lymphoma are eligible if cure is not possible or anticipated. Clinical
Plan to start a new cancer treatment regimen within 4 weeks from time of baseline registration. The treatment regimen is up to the discretion of the treating oncology physician. The regimen must include a chemotherapy drug or other agents that have similar prevalence of toxicity.
study visits.
study at the discretion of the physician and patient.
Treatment: Each institution will be randomized between
Intervention Group: GA + Personal summary & recommendations forms given to subject & doctor
OR
Usual Care Group: GA without summary & recommendations forms
Participant Assessments.
Oncology Physician Assessments.
The oncology physician assessments will be done either on paper or through REDCap, whichever the oncology physician prefers. The baseline and end of study assessments take no longer than 10 minutes and after the initial participant visit, the decision-making
The Delaware Cancer Treatment Program (DCTP) provides medical insurance coverage to uninsured Delawareans for
For information regarding clinical trials
or if you would like to have the list of open protocols e-mailed to you, akee@christianacare.org.
188
Del Med J | June 2017 | Vol. 89
| No. 6
